Jack Meehan

Stock Analyst at Barclays

(3.06)
# 1,198
Out of 5,163 analysts
137
Total ratings
69.51%
Success rate
21.33%
Average return

Stocks Rated by Jack Meehan

Labcorp Holdings
Oct 2, 2025
Maintains: Equal-Weight
Price Target: $275$290
Current: $263.80
Upside: +9.93%
Agilent Technologies
Feb 28, 2024
Maintains: Underweight
Price Target: $120$125
Current: $111.51
Upside: +12.10%
Waters
Aug 3, 2023
Maintains: Equal-Weight
Price Target: $275$288
Current: $286.57
Upside: +0.50%
Avantor
Mar 3, 2021
Initiates: Overweight
Price Target: $33
Current: $7.93
Upside: +316.14%
Illumina
Mar 3, 2021
Initiates: Underweight
Price Target: $325
Current: $118.94
Upside: +173.25%
InMode
Aug 17, 2020
Maintains: Overweight
Price Target: $18$19
Current: $13.54
Upside: +40.32%
Quest Diagnostics
Apr 23, 2020
Maintains: Equal-Weight
Price Target: $93$99
Current: $199.70
Upside: -50.43%
ICON Public Limited Company
Apr 23, 2020
Maintains: Overweight
Price Target: $170$180
Current: $98.33
Upside: +83.06%
Myriad Genetics
Mar 26, 2020
Maintains: Underweight
Price Target: $14$10
Current: $4.66
Upside: +114.59%
IQVIA Holdings
Mar 26, 2020
Maintains: Overweight
Price Target: $192$166
Current: $164.72
Upside: +0.78%
Maintains: Equal-Weight
Price Target: $51$43
Current: $75.12
Upside: -42.76%
Maintains: Equal-Weight
Price Target: $170$154
Current: $155.46
Upside: -0.94%
Maintains: Overweight
Price Target: $435$430
Current: $262.80
Upside: +63.62%
Maintains: Overweight
Price Target: $435$430
Current: $264.40
Upside: +62.63%
Downgrades: Equal-Weight
Price Target: n/a
Current: $17.10
Upside: -
Upgrades: Overweight
Price Target: $52$48
Current: $33.75
Upside: +42.22%
Upgrades: Equal-Weight
Price Target: $720$680
Current: $1,173.74
Upside: -42.07%
Maintains: Underweight
Price Target: $28$30
Current: $68.26
Upside: -56.05%
Maintains: Overweight
Price Target: $295$300
Current: $464.37
Upside: -35.40%
Initiates: Equal-Weight
Price Target: $40
Current: $0.79
Upside: +4,963.29%